Executive summary
US Patent 10,766,965 claims methods for treating relapsed or refractory light chain amyloidosis (AL) using an IgG1 anti-CD38 antibody defined by specific VH and VL variable-region sequences (SEQ ID NO: 4 and SEQ ID NO: 5), including broad sequencing/combination with prior AL regimens (notably bortezomib, ixazomib, cyclophosphamide, and dexamethasone), optional add-ons (e.g., radiotherapy, HSCT), and claims that address functional selectivity constraints (preserving CD38+CD34+ hematopoietic stem cells). The patent’s claim structure is built to read on a class of anti-CD38 therapeutic antibodies in a defined sequence space, with combination and operational timing hooks that can capture real-world AL care pathways and HSCT workflows.
This analysis cannot be completed to the level required for a “comprehensive and critical analysis of the claims and patent landscape” because the full patent record (specification, prosecution history, priority dates, assignees, dependent-claim numbering beyond what you provided, and the complete U.S. and family citation set) is not provided. Without those elements, a defensible, citation-grade landscape mapping (expiration, exclusivity interactions, interferences/obviousness chains, and likely carve-outs from competing anti-CD38 estates) cannot be produced.
US Patent 10,766,965 (anti-CD38 IgG1; SEQ ID NO: 4/5) what does it claim for relapsed refractory light chain amyloidosis?
What the independent claim strategy is
Independent claim coverage is method-focused, anchored on:
- Indication: relapsed or refractory light chain amyloidosis (AL).
- Target/biologic definition: an anti-CD38 IgG1 antibody with VH = SEQ ID NO: 4 and VL = SEQ ID NO: 5.
- Functional objective: “for a time sufficient to treat” the AL condition.
From there, dependent claims expand into:
- Prior-line regimen context (proteasome inhibitor, cyclophosphamide, corticosteroid).
- Combination therapy with “a second therapeutic agent” that includes common AL regimens and immunomodulatory drugs.
- Administration timing (simultaneous/sequential/separate).
- HSCT integration (anti-CD38 plus stem cell transplant in either order).
- A key functional selectivity constraint aimed at avoiding destruction of CD34+ hematopoietic progenitors and, conversely, enabling killing of CD38+ cancer cells via specific mechanisms or CD38 enzymatic modulation.
- Formulation hook: anti-CD38 + hyaluronidase in a composition.
How claim scope is controlled by SEQ ID NOs
The bulk of claim certainty depends on whether SEQ ID NO: 4 and SEQ ID NO: 5 correspond to a specific, commercially known anti-CD38 antibody (or a closely related engineered variant). Your claims also include breadth via “% identity” variants:
- Heavy chain: 95–100% identical to SEQ ID NO: 12
- Light chain: 95–100% identical to SEQ ID NO: 13
- And a specific embodiment: heavy chain SEQ ID NO: 12 + light chain SEQ ID NO: 13
This design can materially broaden coverage to near-identical variants, depending on how the reference sequences relate to the specific SEQ ID NOs named in the core method claims (SEQ ID NO: 4/5 vs 12/13).
What “selective killing” claims actually do
Claims 20 and 21 impose two functional boundaries:
- Claim 20: anti-CD38 does not mediate killing of CD34+ progenitors by CDC.
- Claim 21: anti-CD38 induces killing of CD38+ plasma cells by ADCC, ADCP, CDC, apoptosis, or modulation of CD38 enzymatic activity.
This pair is structurally important because it attempts to reconcile efficacy on malignant plasma cells with avoidance of progenitor loss, a common patentability and safety concern when targeting CD38, which is also present in some hematopoietic compartments.
How HSCT timing is claimed
Claims 26–29 and 32–33 cover HSCT in two procedural directions:
- Anti-CD38 first, then HSCT (claim 26).
- HSCT first, then anti-CD38 (claim 33).
- Claim 32 is a combined “introduce stem cells and administer antibody after introduction” sequence.
This is a litigation-relevant drafting choice because it reduces “design-around” arguments based solely on dosing order.
What patents protect relapsed or refractory light chain amyloidosis using anti-CD38 antibodies?
Patent landscape boundaries you should expect in the anti-CD38 AL space
A typical anti-CD38 patent landscape around AL treatment includes:
- Targeted mAb composition patents (anti-CD38 antibody itself; Fc engineering; variable-region definitions; manufacturing).
- Indication/method-of-use patents for AL (relapsed/refractory or line-specific treatment).
- Combination regimen patents (anti-CD38 + proteasome inhibitor ± immunomodulator ± steroid).
- HSCT-adjunct patents (post-therapy transplant mobilization/conditioning integration; timing; stem cell preservation).
US 10,766,965 is positioned primarily in method-of-use with operational hooks (timing, HSCT ordering, selectivity constraints, and hyaluronidase-containing composition).
How the claim set maps to litigation pressure points
For each competitor anti-CD38 product, the primary infringement disputes usually pivot on:
- Whether the competitor antibody matches the variable-region definitions (exact sequences or identity-defined variants).
- Whether the clinical use qualifies as “relapsed or refractory AL.”
- Whether the regimen includes the claimed combination agents and timing (claims 2–18).
- Whether HSCT is performed and whether CD38+CD34+ cells “survive” as claimed (claims 26–33).
- Whether the competitor’s effector functions align with claim 20/21 constraints (CDC vs ADCC/ADCP; apoptosis; CD38 modulation).
When does US Patent 10,766,965 lose exclusivity and what patent term is relevant?
No definitive expiration or exclusivity calculation can be produced from the claim text alone. A term and exclusivity schedule requires:
- earliest priority date(s),
- filing and grant dates,
- whether a PTA/PTE applies,
- and the family’s jurisdictional timeline.
Because those elements are not provided, any statement about loss of exclusivity would be non-actionable and would fail a precision requirement for a patent-analytic deliverable.
What Paragraph IV challenges are likely for US 10,766,965?
Paragraph IV challenges apply to ANDA/Abbreviated approvals of small molecules and are not the usual trigger for antibody patent estates. The more common litigation route for anti-CD38 biologics is:
- biosimilar litigation under BPCIA,
- or combination-product exclusivity disputes if a biosimilar enters a labeled regimen.
A “likely Paragraph IV” forecast cannot be executed credibly without knowing:
- whether the claims were asserted in any existing litigation,
- whether the underlying antibody is still under regulatory exclusivity,
- and the specific biologic/biosimilar candidates and approval pathway in the relevant label.
No such record is included in your input.
How strong is the patent estate for SEQ ID NO: 4/5 anti-CD38 AL treatment?
Strength factors embedded in the claim drafting
- Sequence specificity: The core claims are anchored in exact VH/VL sequences (SEQ ID NO: 4/5). This increases enforceability against products whose variable regions match or substantially overlap.
- Identity variants: The 95–100% identity language for SEQ ID NO: 12/13 can broaden infringement to “minor” variant designs.
- Operational realism: Claims 2–18 cover common AL regimen elements and timing, reducing gaps between patent text and actual prescribing patterns.
- HSCT sequence capture: Claims are written to catch both ordering approaches (anti-CD38 pre- or post-transplant), reducing an easy workflow design-around.
- Functional selectivity: Claim 20/21 creates a mechanistic boundary that could support non-obviousness arguments and give clearer infringement tests if tied to measurable effector function outcomes.
Weakness factors typically exploited in validity/infringement
Without the specification and prosecution record, the usual weaknesses cannot be tied to this patent with certainty, but claim structure indicates typical friction points:
- Enablement/support: broad mechanism language (ADCC/ADCP/CDC/apoptosis/CD38 modulation) can invite written description or enablement attacks if the specification doesn’t provide support across the breadth for AL and the specific antibody sequences.
- Functional limitations: claim 20’s “does not mediate killing by CDC” is often hard to prove or disprove without robust functional testing and a defined assay framework, which can create evidentiary uncertainty in infringement.
- Selectivity conflation risk: combining “CDC does not kill CD34+ progenitors” with “CDC can kill CD38+ plasma cells” can be challenged as internally inconsistent or insufficiently supported if the specification does not tie these phenomena to the same antibody in the same context.
- Combination breadth: claim 10 lists many agents (including multiple proteasome inhibitors, IMiDs, panobinostat, melphalan, thalidomide/lenalidomide/pomalidomide, etc.), which can invite validity attacks if novelty hinges on a narrower combination not actually supported.
A rigorous strength assessment requires the full claim dependency web, the allowed scope, and the prior art cited during prosecution, none of which are provided.
What formulations are protected by US 10,766,965 (anti-CD38 + hyaluronidase)?
Claim 30 adds a formulation-composition hook:
- anti-CD38 antibody + hyaluronidase.
This resembles the general formulation architecture used for subcutaneous delivery of therapeutic antibodies that include hyaluronidase. If the underlying antibody product is already delivered in a hyaluronidase-enabled format, the claim can overlap with existing commercial product lines, but formulation-specific enforcement still depends on:
- whether the hyaluronidase composition is defined with dosage or specific components in the specification,
- whether the claim is product-agnostic or composition-identity limited.
That resolution is not possible from claims alone.
Which companies are competing in anti-CD38 relapsed refractory AL and what generic/biosimilar entry risks exist?
A company-by-company landscape is not possible from the input. The analysis requires:
- the identities of the VH/VL sequences in SEQ ID NO: 4/5 and SEQ ID NO: 12/13,
- which maps the patent to a specific anti-CD38 antibody (or its engineered variant),
- and then a list of approved competitors, biosimilars in the U.S., and pipeline candidates.
Without the patent specification or at least the sequence mapping, naming specific companies would be speculative.
Key Takeaways
- US Patent 10,766,965 is a method-of-treatment patent for relapsed or refractory AL using an IgG1 anti-CD38 antibody defined by specific VH and VL variable-region sequences (SEQ ID NO: 4 and SEQ ID NO: 5).
- Claim breadth is expanded through: (i) combination with standard AL agents (proteasome inhibitors, cyclophosphamide, corticosteroids, IMiDs, etc.), (ii) flexible administration timing, (iii) integration with HSCT in either procedural order, and (iv) a formulation claim adding hyaluronidase.
- The claims include functional selectivity boundaries aimed at preserving CD34+ hematopoietic progenitors while enabling killing of CD38+ malignant cells.
- A complete exclusivity/expiration timeline, validity-risk assessment vs prior art, and a competitor-by-competitor litigation/biosimilar entry analysis cannot be generated from the claim text alone because the patent record’s bibliographic and family data, and prosecution history, are not provided.
FAQs
-
Does US 10,766,965 cover both pre- and post-HSCT dosing of the anti-CD38 antibody?
Yes, the claim set includes HSCT workflows where the antibody is given before transplant and where the antibody is given after stem cells are introduced.
-
What combination regimens are expressly covered in US 10,766,965?
The patent claims administration with agents including bortezomib, ixazomib, cyclophosphamide, dexamethasone, and additional listed therapeutics in the combination-dependent claims.
-
Are variable-region identity variants included in the infringement scope?
Yes. The claims include heavy and light chains defined by 95–100% identity to specified SEQ ID NO: 12/13 sequences.
-
Does the patent require a specific mechanism of action for killing?
The patent includes dependent functional language on CDC/ADCC/ADCP/apoptosis and CD38 enzymatic activity modulation, plus a progenitor CDC-avoidance restriction.
-
Is hyaluronidase part of the claimed composition?
Yes. Claim 30 includes a pharmaceutical composition comprising the anti-CD38 antibody and hyaluronidase.
References (APA)
- Not provided.
